60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent “The retrograde instillation of JELMYTO for the clinical management of low-grade upper tract urothelial ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback